ADAPTIVE BIOTECHNOLOGIES COR's ticker is ADPT and the CUSIP is 00650F109. A total of 212 filers reported holding ADAPTIVE BIOTECHNOLOGIES COR in Q2 2022. The put-call ratio across all filers is 0.37 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $1,719,245 | -62.0% | 194,705 | -67.1% | 0.01% | -61.5% |
| Q4 2022 | $4,528,129 | +31.9% | 592,687 | +22.9% | 0.03% | +36.8% |
| Q3 2022 | $3,434,000 | +33.8% | 482,309 | +52.0% | 0.02% | +18.8% |
| Q2 2022 | $2,567,000 | -40.3% | 317,327 | +2.4% | 0.02% | -55.6% |
| Q1 2022 | $4,301,000 | +72.9% | 309,850 | +249.7% | 0.04% | +50.0% |
| Q4 2021 | $2,487,000 | +72.0% | 88,615 | +108.3% | 0.02% | +33.3% |
| Q3 2021 | $1,446,000 | +43.2% | 42,533 | +72.1% | 0.02% | +63.6% |
| Q2 2021 | $1,010,000 | -70.0% | 24,710 | -70.5% | 0.01% | -74.4% |
| Q1 2021 | $3,372,000 | +863.4% | 83,764 | +1314.9% | 0.04% | +760.0% |
| Q4 2020 | $350,000 | +118.8% | 5,920 | +80.3% | 0.01% | +150.0% |
| Q3 2020 | $160,000 | +3.2% | 3,283 | +2.6% | 0.00% | -33.3% |
| Q2 2020 | $155,000 | -76.3% | 3,200 | -86.4% | 0.00% | -83.3% |
| Q1 2020 | $655,000 | – | 23,562 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Blue Water Life Science Advisors, LP | 3,030,434 | $23,152,516 | 15.55% |
| BERYLSON CAPITAL PARTNERS, LLC | 289,726 | $2,213,507 | 6.45% |
| Matrix Capital Management Company, LP | 11,572,590 | $88,414,588 | 1.69% |
| Pier Capital, LLC | 1,012,401 | $7,734,744 | 1.27% |
| VIKING GLOBAL INVESTORS LP | 29,993,708 | $229,151,929 | 1.15% |
| Eagle Health Investments LP | 607,860 | $4,644,050 | 1.07% |
| Triatomic Management LP | 130,805 | $999,350 | 0.84% |
| Aristotle Atlantic Partners, LLC | 1,880,567 | $14,367,532 | 0.80% |
| Senator Investment Group LP | 1,000,000 | $7,640,000 | 0.69% |
| ARK Investment Management | 9,201,245 | $70,297,512 | 0.61% |